BAY 3547922

BAY 3547922 is an investigational monoclonal antibody-chelator conjugate developed by Bayer for use in oncology imaging and potential therapy. It is currently being studied in a Phase 1 clinical trial as part of a two-drug protocol for patients with hepatocellular carcinoma (HCC) and other select solid tumors. In this study, BAY 3547922 is administered as the unconjugated monoclonal antibody prior to infusion of a radiolabeled version (BAY 3630942), which allows researchers to track biodistribution using PET/CT imaging. The mechanism of action involves targeting proteins present on the surface of cancer cells, enabling specific localization to tumor tissue; however, the precise molecular target has not been disclosed. The drug has not yet received regulatory approval or an FDA designation[1][2][3][4].